Expert Perspectives Series: A Focus on Lung Cancer – <em>EGFR</em> and <em>ALK</em> - priME Oncology
Expert Perspectives
Expert Perspectives

Expert Perspectives Series: A Focus on Lung Cancer – EGFR and ALK

Not a member of My prIME? Join now for instant access.

Expert Perspectives Series: A Focus on Lung Cancer – EGFR and ALK

View Activity

Activity Overview

This CME-certified activity includes an expert presentation reviewing new data in lung cancer, as well as a patient/physician discussion focusing on the importance of shared decision making in the treatment of lung cancer. The activity also features a series of clinical vignette-style questions, applying the new information to practical case scenarios.


  • Ravi Salgia, MD, PhDCity of Hope Cancer Center
    Duarte, California


  • Elizabeth Lacasia


  • Fractals in Lung Cancer
  • EGFR Mutational Status
  • ALK Translocated Mutational Status
  • Clinical Scenarios
  • The Importance of Shared Decision Making in the Management of Non-Small Cell Lung Cancer (NSCLC)

Target Audience

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with lung cancer.

Learning Objectives

  • Evaluate recent data that have the potential to impact practice, including immune-checkpoint inhibitors, targeted agents, and treatment strategies
  • Identify patients who would most likely benefit from referral to a clinical trial
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by grants from Astellas, Boehringer Ingelheim, Celgene Corporation, Genentech, Lilly, and Merck.

Developed in collaboration with the Addario Lung Cancer Foundation.


Activity Date

April 1, 2016

April 1, 2017